autologous mesenchymal stem cells + c-kit+ cardiac progenitor cells

This investigational cell-based therapy is a combination of autologous bone marrow-derived mesenchymal stem cells (MSCs) and c-kit+ cardiac progenitor cells (CPCs). Developed and evaluated in the Phase II **CONCERT-HF** trial (Combination Of meseNchymal and c-kit+ Cardiac stEm cells as Regenerative Therapy for Heart Failure), the therapy is designed for patients with heart failure secondary to ischemic cardiomyopathy. The treatment is administered via transendocardial injection into the left ventricle. While the cells were originally hypothesized to directly regenerate cardiac tissue, the current scientific consensus suggests they function primarily through paracrine mechanisms, releasing growth factors and cytokines that modulate the immune response, promote angiogenesis, and improve myocardial function. Results from the CONCERT-HF trial indicated that while the combination did not significantly alter left ventricular structure, it was associated with a reduction in major adverse cardiac events (MACE) and improvements in patient quality of life.

Other names

autologous bone marrow-derived mesenchymal stromal cellsMSCsc-kit+ cardiac progenitor cellsCPCsc-kit+ cardiac stem cells